Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer

The prognosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) remained unsatisfactory currently, more anti-HER2 agents are needed. Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used as a monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Cong, Li, Haifeng, Yao, Herui, Lin, Ying, An, Xin, Chen, Meiting, Huang, Riqing, Li, Lu, Hu, Anqi, Ni, Mengqian, Zhang, Lulu, Yang, Wei, Xu, Zhonghui, Li, Su, Shi, Yanxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794829/
https://www.ncbi.nlm.nih.gov/pubmed/36575195
http://dx.doi.org/10.1038/s41523-022-00501-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794829/
https://www.ncbi.nlm.nih.gov/pubmed/36575195
http://dx.doi.org/10.1038/s41523-022-00501-2

Ejemplares similares